Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers

Background: In the LOTIS-2 study, patients (pts) with relapsed/refractory (R/R) DLBCL treated with loncastuximab-tesirine (lonca), a CD19 directed antibody-drug conjugate, demonstrated an overall response rate (ORR) and complete response rate (CRR) of 48.3 % and 24.1%. However, there is a paucity of...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2023-11, Vol.142 (Supplement 1), p.312-312
Hauptverfasser:	Ayers, Emily, Zelikson, Viktoriya, Gurumurthi, Ashwath, Sawalha, Yazeed, Annunzio, Kaitlin, Saha, Aditi, Dong, Ning, Qualls, David Augustus, Amoozgar, Behzad, Kahl, Brad S., Baird, John H., Challa, Pavan, Huntington, Scott F., Santos, Jennifer, Bair, Steven M., Narkhede, Mayur S., Li, Shuning, Frosch, Zachary AK, Ho, Carrie I, Smith, Stephen D, Winter, Allison, Landsburg, Daniel J., Furqan, Fateeha, Hamadani, Mehdi, Baird, Katelin, Romancik, Jason T., Alharthy, Hanan, Law, Jennie, Bojanini, Leyla, Advani, Ranjana H., Hu, Boyu, Johnson, Patrick Connor, Grover, Natalie S., Kundu, Debamita, Merrill, Mwanasha Hamuza, Crombie, Jennifer L, Shafagati, Nazila, Sterling, Cole, Nastoupil, Loretta J., Epperla, Narendranath
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!